Clinical Trial Detail

NCT ID NCT03098550
Title A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

Advanced Solid Tumor

pancreatic adenocarcinoma

triple-receptor negative breast cancer

lung non-small cell carcinoma

Therapies

Daratumumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.